LoginCreate an account

  Username: Password:
 
Error
  • Error loading feed data.
Home

Merck, Portola in $420M deal for anticlotting drug

E-mail Print PDF
User Rating: / 0
PoorBest 

WHITEHOUSE STATION, N.J. (AP) — Merck & Co. and Portola Pharmaceuticals Inc. say they have an exclusive deal to develop and market an experimental drug to prevent strokes in people with a dangerous irregular heart rhythm.

Merck, the world's eighth-biggest drugmaker, will pay Portola $50 million initially to license the drug, called betrixaban.

The drug prevents blood clots by blocking a clotting substance called Factor Xa. The pill would be taken daily by people with atrial fibrillation, a sometimes deadly abnormal heart rhythm.

Betrixaban is currently in mid-stage testing. Merck would cover costs of future testing. If that goes well and the drug is approved for sale, Portola could earn up to $420 million in payments from Merck, plus sales royalties.

 

Copyright 2009 The Associated Press.

 

 
FOX News
FOXNews.com - Breaking news and video. Latest Current News: U.S., World, Entertainment, Health, Business, Technology, Politics, Sports.
FOX News
  • States protect no-cost contraception, vasectomy
    Even before President Elect Donald Trump suggested Obamacare was in jeopardy, Republican cries of "replace and repeal" inspired some states to protect the no-cost contraceptive benefit guaranteed under the federal bill.
  • Dad: Why I'm marching with my daughter
    I'm no joiner, but Trump's behavior has awakened me to how much i care that my daughters can live in a world where a woman controls her own body and future, writes James Kindall.
  • Real survivors get fairy-tale endings
    He seemed like such a nice man, the clean-cut 25-year old who visited a rural Wisconsin church one autumn morning in 1996, looking for a wife.

Search...

WebSite

mySSnews Login



User Menu